Mark Voskoboynik
- Oncology top 5%
- Immunology top 10%
- Molecular Biology
- Pulmonary and Respiratory Medicine
- Cancer Research
- Co-authors
- Elliot ChartashKathryn F. MilehamAdnan NagrialJane HealyTodd M. BauerD.H. LeeCorinne Maurice‐DrorHyun Cheol Chung
- Topics
- Cancer Immunotherapy and Biomarkers (37 papers)CAR-T cell therapy research (18 papers)Lung Cancer Treatments and Mutations (9 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaCancer
- Partner nations
- AustraliaUnited StatesChina
In The Last Decade
Mark Voskoboynik
70 papers receiving 674 citations
Hit Papers
Peers
Comparison fields: 5 of 65
- Oncology 504
- Immunology 233
- Molecular Biology 181
- Pulmonary and Respiratory Medicine 165
- Cancer Research 53
Countries citing papers authored by Mark Voskoboynik
This map shows the geographic impact of Mark Voskoboynik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Voskoboynik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Voskoboynik more than expected).
Fields of papers citing papers by Mark Voskoboynik
This network shows the impact of papers produced by Mark Voskoboynik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Voskoboynik. The network helps show where Mark Voskoboynik may publish in the future.
Co-authorship network of co-authors of Mark Voskoboynik
This figure shows the co-authorship network connecting the top 25 collaborators of Mark Voskoboynik. A scholar is included among the top collaborators of Mark Voskoboynik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Voskoboynik. Mark Voskoboynik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 5 | |
| 3 | 1 | |
| 4 | 0 | |
| 5 | 1 | |
| 6 | 15 | |
| 7 | 10 | |
| 8 | 1 | |
| 9 | 5 | |
| 10 | 4 | |
| 11 | 2 | |
| 12 | First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆breakdown → | 196 |
| 13 | 26 | |
| 14 | 3 | |
| 15 | 1 | |
| 16 | 12 | |
| 17 | 2 | |
| 18 | 6 | |
| 19 | 2 | |
| 20 | 2 |
About Mark Voskoboynik
Mark Voskoboynik is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 76 papers that have together received 678 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (37 papers), CAR-T cell therapy research (18 papers) and Lung Cancer Treatments and Mutations (9 papers). The work is most often cited by research in Oncology (504 citations), Immunology (233 citations) and Pulmonary and Respiratory Medicine (165 citations). Mark Voskoboynik has collaborated with scholars based in Australia, United States and China. Frequent co-authors include Elliot Chartash, Kathryn F. Mileham, Adnan Nagrial, Jane Healy, Todd M. Bauer, D.H. Lee, Corinne Maurice‐Dror, Hyun Cheol Chung, Jiaxin Niu and Vincent Chung. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.